Previous 10 | Next 10 |
2024-05-18 11:18:53 ET Summary Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerability and how CT-388 stacks up against key competito...
2024-05-18 02:35:00 ET Danish pharmaceutical company Novo Nordisk (NYSE: NVO) has established itself as one of the top healthcare stocks in the world with a market cap hovering around $600 billion. Long-term investors earned fantastic returns; in just five years, the share prices of...
2024-05-16 13:37:18 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...
2024-05-16 09:25:33 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk owner to acquire major stake in Aust...
2024-05-16 06:48:39 ET More on Roche Roche: Value Remains Despite Covid-19 Revenue Growth Loss Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript Q1 2024 Sales/ Trading Statement Call J&J, Roche, AstraZeneca poised to have highest or...
2024-05-15 10:37:00 ET It's a good bet that, five years ago, the average American investor would not have been familiar with Novo Nordisk (NYSE: NVO) . That's because the Denmark-based company had not yet won U.S. Food and Drug Administration (FDA) approval for its star drug, weight...
2024-05-15 09:34:32 ET More on Danaher, Novo Nordis, etc. Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation ...
2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...
2024-05-15 06:45:00 ET Ozempic, Ozempic, Ozempic. As we all know, Novo Nordisk 's (NYSE: NVO) highly successful drug for type 2 diabetes is grabbing headlines, shrinking waistlines and enriching investors. And thanks to a big investment in a new development partnership, there co...
2024-05-14 14:42:53 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk: Patients on Wegovy maintain weight ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...